Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1–Selected Non-Small Cell Lung Cancer

2021 ◽  
Author(s):  
Jacek Jassem ◽  
Filippo de Marinis ◽  
Giuseppe Giaccone ◽  
Alain Vergnenegre ◽  
Carlos H. Barrios ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Survival Analysis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Platinum Based Chemotherapy ◽  
Treatment Naïve ◽  
Overall Survival Analysis

Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population

2018 ◽  
Vol 54 (1) ◽  
pp. 10-17
Author(s):  
Filipa Aguiar ◽  
Gabriela Fernandes ◽  
Henrique Queiroga ◽  
José Carlos Machado ◽  
Luís Cirnes ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Survival Analysis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Mutated ◽  
Overall Survival Analysis

Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population

2018 ◽  
Vol 54 (1) ◽  
pp. 10-17 ◽  
Author(s):  
Filipa Aguiar ◽  
Gabriela Fernandes ◽  
Henrique Queiroga ◽  
José Carlos Machado ◽  
Luís Cirnes ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Survival Analysis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Mutated ◽  
Overall Survival Analysis

“My Patient Was Diagnosed With Nontargetable Advanced Non–Small Cell Lung Cancer. What Now?” Diagnosis and Initial Treatment Options for Newly Diagnosed Patients With Advanced NSCLC

2018 ◽  
pp. 696-707 ◽  
Author(s):  
Melissa Johnson ◽  
Nathan A. Pennell ◽  
Hossein Borghaei
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
The United States ◽  
Small Cell ◽  
Small Cell Lung ◽  
Platinum Based Chemotherapy ◽  
Treatment Naïve ◽  
Novel Therapeutic Strategies

Although lung cancer remains the leading cause of cancer-related mortality in the United States and worldwide, the rate at which Americans are dying from lung cancer is declining. Improving survival can be explained, in large part, by a growing understanding of the heterogeneous biology of non–small cell lung cancer (NSCLC) as well as recent successes of novel therapeutic strategies more effective and tolerable than platinum-based chemotherapy. We now recognize distinct subtypes of NSCLC, defined by molecular profiling and immunohistochemistry, with different treatment algorithms, including targeted small molecular inhibitors and immunotherapy for each. Both biomarker selection and preferred frontline strategies continue to evolve rapidly, making it difficult for many practitioners to keep up. In this review, we will first describe the recommended initial workup for a patient with advanced or metastatic NSCLC in 2018; next, we present an algorithm to aid oncologists in the selection of the most appropriate therapy for treatment-naive patients with NSCLC, and finally, we offer a look into future treatment options through a discussion of ongoing clinical trials.

scholarly journals Survival Analysis in Advanced Non Small Cell Lung Cancer Treated with Platinum Based Chemotherapy in Combination with Paclitaxel, Gemcitabine and Etoposide

2013 ◽  
Vol 14 (8) ◽  
pp. 4661-4666 ◽  
Author(s):  
Kirmani Natukula ◽  
Kaiser Jamil ◽  
Usha Rani Pingali ◽  
Venkata Satya Suresh Attili ◽  
Umamaheshwar Rao Naidu Madireddy
Keyword(s):  
Lung Cancer ◽  
Survival Analysis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Platinum Based Chemotherapy

scholarly journals Overall Survival of Patients With ALK-Positive Metastatic Non–Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study

2019 ◽  
pp. 1-7 ◽  
Author(s):  
Ilya Tsimafeyeu ◽  
Fedor Moiseenko ◽  
Sergei Orlov ◽  
Elena Filippova ◽  
Alexander Belonogov ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Cohort Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Metastatic Nsclc ◽  
Platinum Based Chemotherapy ◽  
Alk Positive

PURPOSE The overall survival (OS) results in patients with ALK-positive metastatic non–small-cell lung cancer (NSCLC) have rarely been reported. The aim of this prospective-retrospective cohort study was to obtain real-world data on the use of crizotinib or chemotherapy in patients with ALK-positive metastatic NSCLC in Russia. PATIENTS AND METHODS Patients with epidermal growth factor receptor–negative metastatic NSCLC were screened in 23 cancer centers. To be eligible, patients were required to have confirmation of ALK rearrangement. Patients were treated with crizotinib (250 mg twice daily; n = 96) or the investigator’s choice of platinum-based chemotherapy (n = 53). The primary end point was OS. RESULTS A total of 149 ALK-positive patients were included. Mean age was 53 years in both groups. Patients were predominately women (59%) and never-smokers (74%), and most patients had adenocarcinoma histology (95%). At a median follow-up time of 15 months, 79 of the 149 patients included in the analysis had died. Median OS from the start of treatment was 31 months (95% CI, 28.5 to 33.5 months) in the crizotinib group and 15.0 months (95% CI, 9.0 to 21.0 months) in the chemotherapy group ( P < .001). The objective response rate was 34% in the crizotinib group. Among patients with brain metastasis, one complete response (6%) and five partial responses (31%) were achieved. Grade 3 adverse events were observed in three patients (3%) in the crizotinib group. CONCLUSION The improved OS observed in crizotinib clinical trials in ALK-positive NSCLC was also observed in the less selective patient populations treated in daily practice in Russia. The use of standard chemotherapy in these patients remains common but seems inappropriate as a result of the effectiveness of newer treatments, such as crizotinib.

Sign in / Sign up

Export Citation Format

Share Document